VisionMD

The site for all things eye-related

Artificial retina FDA approved

bionic eye3 months ago, I wrote that the Argus II artificial retina implant had been recommended for FDA approval. 3 days ago, the FDA actually approved the device.

This is exciting news because the Second Sight device is the first bionic eye approved for patients in the US.  The Argus II is the first treatment in existence that can replace the function of lost photoreceptors (light sensing cells) in the eye.

How it works

The device transmits images from a small, eye-glass-mounted camera to a microelectrode array implanted on a patient’s damaged retina. The patient gets about 20 degrees of visual field.

Who can get it?

The FDA approved the device for people who have lost sight from retinitis pigmentosa (RP), which affects one in every 4,000 Americans.

What can they see?

The implant allows RP patients who are completely blind to locate objects, detect movement and discern shapes such as large letters. Pretty amazing considering that these patients were completely blind prior to the surgery.

Long time coming

The research team began their work in he 1980s and have received close to $200 million in funding from both governmental (NSF, NIH, DOE) and private sources to bring this device to market.

The price of this device is speculated to be around $100,000. There is no word yet about insurance coverage.

.

Photo credit: nsf.gov

(Note: I have no financial relationship to the company or products described in this post.)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Join 1,451 other followers

Blog Stats

  • 196,672 hits
%d bloggers like this: